If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
ZypAdhera® (olanzapine pamoate): Use With COVID-19 Vaccines
The use of vaccines against SARS-CoV-2 in patients treated with olanzapine long-acting injection has not been studied.
of COVID-19 Vaccines to Patients Receiving Olanzapine Pamoate
acute respiratory syndrome coronavirus 2 is an emerging virus that
has caused the recent COVID-19 pandemic.1
Recently, vaccines have been developed against SARS-CoV-2 and
additional vaccines are expected to be available in the coming
Vaccination With Olanzapine Long-acting Injection
use of a SARS-CoV-2 vaccine in patients treated with olanzapine
pamoate has not been studied by Lilly.
regarding the use of any vaccination, including SARS-CoV-2 vaccines,
in patients treated with olanzapine pamoate should be made at the
discretion of the prescribing physician using their best clinical
judgment, and must be made by the clinician after careful
consideration of risk factors of the patient as well as the risks and
benefits of vaccination. Consultation with an infectious disease
expert may be helpful in high-risk or emergency situations such as
the current COVID-19 pandemic.
Su Z, Wen J, McDonnell D, et al. Vaccines are not yet a silver
bullet: The imperative of continued communication about the
importance of COVID-19 safety measures. Brain Behav Immun Health.
= coronavirus disease 2019
= long-acting injection
= Eli Lilly and Company
= severe acute respiratory syndrome coronavirus 2
Date of Last Review:January 15, 2021
Are you satisfied with this content?
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at firstname.lastname@example.org